PATENT CLAIM ANALYSIS

Application Number: 15742867
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "317000"]

Abstract:
The invention relates to antagonists of integrin α4 and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for treating ocular inflammatory conditions, such as dry eye disease, non-infectious uveitis (e.g., anterior, intermediate, posterior, pan-uveitis), non-infectious conjunctivitis, iritis, or scleritis in animals, and particularly mammals, including humans.

Claim (Index 2):
The pharmaceutical composition of  claim 1 , wherein the composition is suitable for ocular administration.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 86.0
- Lexical Diversity: 1.38
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15676968', '13304292', '13601258', '15080893', '14857758']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8031939226626059
- 35 USC 102 Novelty (BERT): 0.5074718537626272
- Combined Prediction Score: 0.773621715772608
- Mean Citation Score: 255.577264
- Max Citation Score: 266.30417
- Similarity Product: 189.13241512385608

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test